TYGRIS · 101-MS-403
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A prospective, open-label, international, multicenter observational study assessing the safety of Tysabri (natalizumab) for relapsing-remitting multiple sclerosis. NCT00483847.
Sponsor: BIOGEN
Phase: IV
Area: Neuroimmunology